ArticleFrontiers in pharmacology2025
Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson's disease: a disproportionality analysis of the FAERS database.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Catecholaminergic storm and extreme blood pressure lability induced by combined levodopa/benserazide, selegiline, and piribedil in Parkinson's disease: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Neuroprotective role ofFrontiers in nutrition · 2026Article
- Synergistic Effects of Levodopa, Benserazide, and Nortriptyline on Behavioral Impairments and Brain Pathology in an Experimental Rat Model of Parkinson's Disease.Neurology research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Levodopa-induced motor complications are a significant concern in the treatment of Parkinson's disease (PD). Dopamine decarboxylase inhibitors (DCIs) such as benserazide (BSZ) and carbidopa (CD) are commonly used in conjunction with levodopa to manage PD symptoms. However, their association with motor complications remains unclear. Methods: We performed a retrospective pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) data from Q1 2004 to Q2 2024. The study included only adverse event reports (AERs) related to oral administration of drugs indicated for PD. We concentrated on motor complications, selecting two system organ classes (SOCs) associated with motor fluctuations and dyskinesia: nervous system disorders and general disorders/administration site conditions. Disproportionality analysis and Bayesian methods were utilized to identify and assess motor complication signals associated with BSZ and CD. A signal was deemed significant if it met the following criteria: reporting odds ratio (ROR) ≥ 3 with a 95% confidence interval (CI) lower bound >1, information component (IC) 95% CI lower bound >0, and empirical Bayes geometric mean (EBGM) 95% CI lower bound >2. Results: The analysis identified 8,744 AERs related to motor complications, recording 19,482 adverse events (AEs). The study highlighted motor complications such as dyskinesia, the on-off phenomenon, freezing episodes, and wearing-off, linked to the oral use of both BSZ and CD. Dyskinesia showed high RORs for both BSZ (16.5, 95% CI 14.76-18.45) and CD (13.81, 95% CI 13.02-14.65). The on-off phenomenon demonstrated a more pronounced ROR for BSZ at 170.74 (95% CI 145.03-201.01) compared to CD at 67.5 (95% CI 59.46-76.63). Wearing-off was notably higher for CD, with an ROR of 7.66 (95% CI 7.08-8.28), compared to BSZ's ROR of 3.03 (95% CI 2.37-3.88). Conclusion: The findings indicate that the choice of DCI affects the risk profile of motor complications in PD. BSZ is associated with increased risks of dyskinesia and the on-off phenomenon, whereas CD is linked to a higher risk of wearing-off. Future research should explore the mechanisms underlying these differences to guide the selection of the most appropriate DCI for individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.